24/7 Market News Snapshot 13 May, 2025 – HCW Biologics Inc. Common Stock (NASDAQ:HCWB)

May 13, 2025

DENVER, Colo., 13 May, 2025 (www.247marketnews.com) – (NASDAQ:HCWB) are discussed in this article.
HCW Biologics Inc. (NASDAQ:HCWB) has recently experienced a substantial increase in its market valuation, with shares rising to $9.12 in pre-market trading, a remarkable 75.05% surge from the previous close of $5.21. The heightened interest among investors is evidenced by an impressive trading volume of 2.26 million shares, signaling robust bullish momentum within the biotech sector. This development suggests a growing optimism regarding the company’s innovations and their potential impact on the market.

In parallel to this surge in stock price, HCW Biologics is making headlines for its advancements in the field of immunotherapy. At the 2025 Annual Meeting of the American Association of Immunologists, the company unveiled groundbreaking research on its proprietary fusion protein, HCW9206. This novel fusion protein is designed to enhance the generation of chimeric antigen receptor T-cells (CAR-Ts), promising improvements in both clinical efficacy and cost-effectiveness for immunotherapy treatments.

Research conducted by Dr. Harris Goldstein’s laboratory emphasizes HCW9206’s capabilities to offer synergistic signals through a single molecule, outperforming traditional methodologies that typically rely on a combination of compounds for CAR-T transduction. The results indicate that CAR-T cells produced with HCW9206 demonstrate superior expansion of stem cell-like memory T cells (Tscm), a factor critical for long-term patient responses.

Experimental studies utilizing humanized mouse models illustrate that CAR-T cells generated with HCW9206 possess notable efficacy in combating both HIV-1 and leukemic cells. This breakthrough suggests a significant shift in CAR-T production methodology, prioritizing enhanced potency and long-lasting patient outcomes.

Dr. Hing C. Wong, CEO of HCW Biologics, expressed enthusiasm about the implications of HCW9206, highlighting its potential to revolutionize CAR-T manufacturing while reducing costs. The company is actively pursuing commercial partnerships to leverage this innovative technology, aiming to advance patient care in cancer and autoimmune disease treatments.

Related news for (HCWB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.